Latest Content

The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.

Nicole Haessly, OD, FAAO, discusses common unsafe contact lens habits, overlooked care steps, and how lens innovations have improved safety.

Amanda Nanasy, OD, discussed how sports can open the door to eye care for underserved athletes and what goes into her performance vision evaluations.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host Diana Canto-Sims, OD.

Amanda Nanasy, OD, described how her own concussion shaped her approach to athletes and why she ties every vision evaluation back to the demands of their sport.

Zachary Keaney, CPOA, discusses the lens care steps patients skip most often and why early diagnosis of lens-related keratitis is critical.

This week's top stories include breaking FDA approvals, insights on AI-assisted front desk management, and more.

Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.

Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.